Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Go back to Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death| Pfizer Inc. (NYSE: PFE) | Delayed: 25.08 -0.13 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.21 | 52 Week High | $37.39 | |||
| Open | $25.22 | 52 Week Low | $28.25 | |||
| Day High | $25.31 | P/E | 15.20 | |||
| Day Low | $24.96 | EPS | $1.65 | |||
| Volume | 41,061,133 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 25.08 -0.13 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.21 | 52 Week High | $37.39 | |||
| Open | $25.22 | 52 Week Low | $28.25 | |||
| Day High | $25.31 | P/E | 15.20 | |||
| Day Low | $24.96 | EPS | $1.65 | |||
| Volume | 41,061,133 | |||||
